Phibro Animal Health | PAHC - 税前利润

金融业

USD

USD 1.41B

现金及等价物

USD 55.49M

USD 240.42M

USD 862.19M

USD 282.37M

USD 474.17M

股息收益率

1.29

USD 54.99M

USD 68.1M

1.92K

EPS每股收益

USD 0.78

股本和储备

USD 332.36M

USD 133.5M

债务利息支出

USD 11.91M

USD 0.08

USD 603.6M

USD 2.21B

USD 27.46M

USD 332.36M

USD 54.99M

普通股股本

USD 40.48M

13.82

USD 38.63M

USD 373.91M

销售和管理费用

USD 78.32M

USD 517.35M

贸易债权人

USD 133.3M

应收帐款人

USD 215.87M

	税前利润	更改		日
Align Technology	USD 148.89M		27.71M	2026-03
ANI Pharmaceuticals	USD 49.52M		39M	2025-09
Assertio Holdings	USD -2.88M		648K	2024-09
Aurora Cannabis	CAD -1.58M		48.55M	2025-12
Bristol-Myers Squibb	USD 1.47B		1.64B	2025-12
Canopy Growth	CAD -62.26M		60.84M	2025-12
Corcept Therapeutics	USD 9.91M		5.33M	2025-12
Eli Lilly	USD 8.27B		1.03B	2025-12
Henry Schein	USD 133M		4M	2025-12
Idexx Laboratories	USD 355.44M		48.46M	2026-03
Knight Therapeutics	CAD -1.92M		13.69M	2025-09
Merck	USD 3.42B		3.32B	2025-12
Nektar Therapeutics	USD -34.7M		2.35M	2025-12
Pacira	USD 571K		8.95M	2025-12
Phibro Animal Health	USD 38.62M		1.26M	2025-12
Prestige Brands	USD 61.81M		7.32M	2025-12
Supernus Pharmaceuticals	USD -5.95M		4.04M	2026-03
Zoetis	USD 887M		15M	2025-09